At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 122 enrolled
Drug / intervention
B244 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating B244 and Vehicle for Atopic Dermatitis Eczema. Completed, enrolled 122 participants across 17 sites.
Detailed Summary
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis Eczema
CountriesUnited States
CollaboratorsVeristat, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartJan 2018
Primary CompletionFeb 2019
Study CompletionMar 2019
TodayJul 2026
First PostedAug 1, 2017
Enrollment StartJan 15, 2018
Primary CompletionFeb 27, 2019
Study CompletionMar 20, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.9 years ago
Interventions
B244biological
B244 suspension
Vehiclebiological
Vehicle suspension